Free Trial

Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S logo
$18.82 +0.16 (+0.86%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$18.68 -0.14 (-0.74%)
As of 04/2/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
9

Based on 13 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 3 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for GMAB.

Consensus Price Target

$41.33
119.62% Upside
According to the 13 analysts' twelve-month price targets for Genmab A/S, the average price target is $41.33. The highest price target for GMAB is $50.00, while the lowest price target for GMAB is $27.00. The average price target represents a forecasted upside of 119.62% from the current price of $18.82.
Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

Sign Up

GMAB Analyst Ratings Over Time

TypeCurrent Forecast
4/3/24 to 4/3/25
1 Month Ago
3/4/24 to 3/4/25
3 Months Ago
1/4/24 to 1/3/25
1 Year Ago
4/4/23 to 4/3/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$41.33$42.17$45.20$48.50
Forecasted Upside119.62% Upside80.74% Upside110.53% Upside65.53% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Remove Ads

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genmab A/S Stock vs. The Competition

TypeGenmab A/SMedical CompaniesS&P 500
Consensus Rating Score
2.69
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside119.62% Upside19,032.97% Upside17.75% Upside
News Sentiment Rating
Positive News

See Recent GMAB News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/1/2025Sanford C. Bernstein
4 of 5 stars
J. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform
3/11/2025Truist Financial
2 of 5 stars
Asthika Goonewardene
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$50.00 ➝ $45.00+122.28%
3/11/2025William Blair
1 of 5 stars
Matt Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
2/13/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Chang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
2/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jonathan Chang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$27.00+37.13%
2/11/2025BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
V. Floc'h
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
1/23/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Raghuram Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+138.44%
11/8/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$46.00 ➝ $48.00+110.25%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Q. Ding
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
9/11/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$31.00 ➝ $31.00+15.63%
8/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Neutral
7/15/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Campbell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Outperform
6/27/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$46.00 ➝ $47.00+83.09%
1/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell
12/6/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
11/10/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
11/8/2023DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Buy
10/12/2023Nordea Equity Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:50 AM ET.


Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 31, 2025. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Analysts have recently increased their earnings per share estimates for FY2028 to $4.06, indicating positive growth expectations for the company.
  • Genmab A/S reported a strong quarterly earnings result of $0.57 per share, significantly surpassing the consensus estimate of $0.28, showcasing its robust financial performance.
  • The stock is currently trading at $20.80, which is relatively low compared to its one-year high of $31.02, suggesting potential for price appreciation.
  • With a return on equity of 16.78% and a net margin of 36.30%, Genmab A/S demonstrates strong profitability and efficient use of shareholder equity.
  • The company has received multiple "buy" ratings from analysts, reflecting a generally positive outlook and confidence in its future performance.

Genmab A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Genmab A/S for these reasons:

  • Despite positive earnings forecasts, the current consensus estimate for full-year earnings remains relatively low at $1.45 per share, which may not meet investor expectations.
  • Truist Financial recently lowered its price target for Genmab A/S from $50.00 to $45.00, indicating a more cautious outlook on the stock's potential upside.
  • The stock has a price-to-earnings (P/E) ratio of 11.95, which, while not excessively high, may suggest limited growth potential compared to higher-growth stocks.
  • Market volatility and economic uncertainties could impact the stock's performance, as evidenced by fluctuations in trading volume and price over the past year.
  • There is a significant number of analysts rating the stock as a "hold," which may indicate a lack of strong conviction in its growth trajectory among some market participants.

GMAB Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $41.33, with a high forecast of $50.00 and a low forecast of $27.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GMAB shares.

According to analysts, Genmab A/S's stock has a predicted upside of 119.62% based on their 12-month stock forecasts.

Over the previous 90 days, Genmab A/S's stock had 4 upgrades and 1 downgrade by analysts.

Genmab A/S has been rated by research analysts at BNP Paribas, HC Wainwright, Leerink Partners, Leerink Partnrs, Sanford C. Bernstein, Truist Financial, and William Blair in the past 90 days.

Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.69 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GMAB compares to other companies.


This page (NASDAQ:GMAB) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners